Therapeutic potential of implanted tissue-engineered bioartificial muscles delivering recombinant proteins to the sheep heart

Ann N Y Acad Sci. 2002 Jun:961:78-82. doi: 10.1111/j.1749-6632.2002.tb03055.x.

Abstract

Tissue-engineered primary adult sheep muscle cells genetically engineered to express either rhVEGF or rhIGF-1 secreted the bioactive proteins locally in the sheep heart for at least 30 days.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Biocompatible Materials*
  • Endothelial Growth Factors / biosynthesis
  • Endothelial Growth Factors / genetics
  • Genetic Therapy / methods
  • Immunohistochemistry
  • Insulin-Like Growth Factor I / biosynthesis
  • Insulin-Like Growth Factor I / genetics
  • Lymphokines / biosynthesis
  • Lymphokines / genetics
  • Muscle, Skeletal / cytology
  • Muscles / cytology*
  • Myocardium / cytology*
  • Neovascularization, Physiologic
  • Recombinant Proteins / metabolism
  • Sheep
  • Time Factors
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Biocompatible Materials
  • Endothelial Growth Factors
  • Lymphokines
  • Recombinant Proteins
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Insulin-Like Growth Factor I